Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

XBI Guru Trades in

XBI Guru Trades in

Q1 2016

XBI Guru Trades in Q1 2016

First Eagle Investment 18,150 sh (New)
» More
Q2 2016

XBI Guru Trades in Q2 2016

Steven Cohen 191,000 sh (New)
First Eagle Investment 18,150 sh (unchged)
» More

Ratios

vs
industry
vs
history
P/B 5.24
XBI's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 5.24 )
Ranked among companies with meaningful P/B only.
XBI' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.61
Current: 5.24
0
5.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.42
XBI's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.42 )
Ranked among companies with meaningful Dividend Yield only.
XBI' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.5
Current: 0.42
0
0.5
Yield on cost (5-Year) 0.42
XBI's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.42 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XBI' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.5
Current: 0.42
0
0.5

More Statistics

Short Percentage of Float0.00%
52-Week Range $44.16 - 73.80
Shares Outstanding (Mil)39,300,000.00
» More Articles for XBI

Headlines

Articles On GuruFocus.com
Twitter Considering Buyout Sep 26 2016 
Presidential Debate a Factor for the Market This Week Sep 26 2016 
Newmont Determined to Acquire Barrick's Stake in the Super Pit Sep 26 2016 
Gurus Invest in Undervalued Retail Companies Sep 26 2016 
Yelp CEO Sells Shares in Company Sep 26 2016 
Tom Russo's 1st Quarter Semper Vic Partners Investor Letter Sep 26 2016 
Tom Russo Comments on MasterCard Sep 26 2016 
Tom Russo Comments on Wells Fargo Sep 26 2016 
Tom Russo Comments on Compagnie Financièr Richemont, SA Sep 26 2016 
Deutsche Bank Is Over-Leveraged Sep 26 2016 

More From Other Websites
[$$] Biotech Is Cheaper Than Big Pharma Sep 24 2016
Gilead Sciences: Another Blow to R&D Strategy Sep 22 2016
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain Sep 21 2016
Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment Sep 21 2016
Biotech ETF At Best Level Since January; Are You Braced For Bumps? Sep 20 2016
How Ionis’s Revenue Trends Are Changing Sep 20 2016
Charting the S&P 500’s bullish-leaning holding pattern ahead of the Fed Sep 20 2016
Tuesday links: personal well-being Sep 20 2016
The Week Ahead: Should You Care About The 'Bulls No.1 Lie?' Sep 17 2016
A Battered Biotech ETF can Rise Again Sep 16 2016
Biotech bright spots Sep 15 2016
A Good Trader Should Be Able to Adjust to Changing Markets Sep 14 2016
Inside the Recent Surge in Biotech ETFs Sep 14 2016
Applied Genetics’ stock suffers record plunge to record low Sep 13 2016
3 Reasons to Buy Teva Right Now Sep 13 2016
Biotech ETFs: Rallying Because Hillary Clinton Has Pneumonia? Sep 12 2016
Here Are the Latest Analyst Recommendations for Biogen Sep 09 2016
Understanding Incyte’s Revenue Stream in 2Q16 Sep 02 2016
Clinton's Proposal To Combat Drug Price Hikes Sep 02 2016
Biotech ETF Industry Outlook Aug 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK